YIELD10 BIOSCIENCE, INC.: Nasdaq/NYSE listing notice — Yield10 receives Nasdaq delisting notice for failure to meet stockholders' equity extension terms

YIELD10 BIOSCIENCE, INC.

On Nov 15, 2023, Nasdaq notified Yield10 it did not meet terms of extension to comply with minimum $2.5M stockholders' equity requirement.
Company failed to complete a planned $12M capital raise or finalize a definitive Camelina feedstock oil agreement with Marathon Petroleum.
Outstanding $1M note from Marathon was not converted to common stock as part of the compliance plan.
Yield10 also faces a separate Nasdaq deficiency for bid price below $1.00 per share since Sept 25, 2023.
Company has appealed to the Nasdaq Hearings Panel, which stays any delisting action pending the hearing outcome.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

YIELD10 BIOSCIENCE, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

September 25, 2023, the Company also received a deficiency letter from the Staff notifying the Company that it was not in compliance with the requirement to maintain a minimum bid price of at least $1.00 per share pursuant to Nasdaq Listing Rule 5550(a)(2). The Company is diligently working to regain compliance with all applicable Nasdaq listing criteria; however, there can be no assurance that a hearing with the Panel will be successful or, if the Panel determines to continue the Company’s listing, that the Company will be able to satisfy the continued listing criteria subsequent to the heari

View on SEC.gov

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

YIELD10 BIOSCIENCE, INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

ng process has concluded. As previously disclosed, on September 25, 2023, the Company also received a deficiency letter from the Staff notifying the Company that it was not in compliance with the requirement to maintain a minimum bid price of at least $1.00 per share pursuant to Nasdaq Listing Rule 5550(a)(2). The Company is diligently working to regain compliance with all applicable Nasdaq listing criteria; however, there can be no assurance that a hearing with the Panel will be successful or, if the Panel determines to continue the Company’s listing, that the Company will be able to satisfy

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001121702-23-000073

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.